JP2002531137A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531137A5
JP2002531137A5 JP2000586938A JP2000586938A JP2002531137A5 JP 2002531137 A5 JP2002531137 A5 JP 2002531137A5 JP 2000586938 A JP2000586938 A JP 2000586938A JP 2000586938 A JP2000586938 A JP 2000586938A JP 2002531137 A5 JP2002531137 A5 JP 2002531137A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000586938A
Other languages
Japanese (ja)
Other versions
JP4240818B2 (ja
JP2002531137A (ja
Filing date
Publication date
Priority claimed from US09/209,916 external-priority patent/US6358703B1/en
Application filed filed Critical
Publication of JP2002531137A publication Critical patent/JP2002531137A/ja
Publication of JP2002531137A5 publication Critical patent/JP2002531137A5/ja
Application granted granted Critical
Publication of JP4240818B2 publication Critical patent/JP4240818B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000586938A 1998-12-10 1999-12-08 第ｖｉｉｉ因子のための発現系 Expired - Lifetime JP4240818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/209,916 1998-12-10
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
PCT/US1999/029169 WO2000034505A1 (en) 1998-12-10 1999-12-08 Expression system for factor viii

Publications (3)

Publication Number Publication Date
JP2002531137A JP2002531137A (ja) 2002-09-24
JP2002531137A5 true JP2002531137A5 (https=) 2005-11-17
JP4240818B2 JP4240818B2 (ja) 2009-03-18

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586938A Expired - Lifetime JP4240818B2 (ja) 1998-12-10 1999-12-08 第ｖｉｉｉ因子のための発現系

Country Status (26)

Country Link
US (10) US6358703B1 (https=)
EP (1) EP1137797B1 (https=)
JP (1) JP4240818B2 (https=)
KR (1) KR100616028B1 (https=)
AT (1) ATE412765T1 (https=)
AU (1) AU761801B2 (https=)
BG (1) BG65431B1 (https=)
BR (1) BRPI9916069B8 (https=)
CA (1) CA2354845C (https=)
CZ (1) CZ302330B6 (https=)
DE (1) DE69939839D1 (https=)
DK (1) DK1137797T3 (https=)
ES (1) ES2315026T3 (https=)
HU (1) HU228489B1 (https=)
IL (2) IL143353A0 (https=)
NO (1) NO329544B1 (https=)
NZ (1) NZ512234A (https=)
PL (1) PL200676B1 (https=)
PT (1) PT1137797E (https=)
RO (1) RO121604B1 (https=)
RU (1) RU2249041C2 (https=)
SI (1) SI20644B (https=)
SK (1) SK286945B6 (https=)
TR (1) TR200101592T2 (https=)
UA (1) UA77383C2 (https=)
WO (1) WO2000034505A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
KR100581574B1 (ko) * 2000-03-22 2006-05-22 옥타게네 게엠베하 인간 세포주 내 재조합 혈액 응고 인자의 제조
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2253644B1 (en) 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
KR101005967B1 (ko) 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
KR20110033242A (ko) * 2008-06-25 2011-03-30 바이엘 헬스케어 엘엘씨 면역원성이 감소된, 인자 ⅷ 뮤테인
CN102119172A (zh) 2008-08-21 2011-07-06 奥克塔法马股份有限公司 重组制备的人类因子viii和ix
US20110178019A1 (en) * 2008-09-03 2011-07-21 Brita Rippner New protecting compositions for recombinantly produced factor viii
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010111414A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
RU2600886C2 (ru) * 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
KR102415992B1 (ko) 2016-04-15 2022-07-04 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법을 제공하는 방법 및 장치
JP7618383B2 (ja) 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US20200245667A1 (en) * 2017-09-13 2020-08-06 Evolve Biosystems, Inc. Oligosaccharide compositions and their use during transitional phases of the mammalian gut microbiome
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
US12252528B2 (en) * 2018-10-23 2025-03-18 The Children's Hospital Of Philadelphia Compositions and methods for modulating Factor VIII function

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
EP0254076B1 (en) * 1986-07-11 1991-05-08 Miles Inc. Improved recombinant protein production
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
CA2075206C (en) * 1989-12-01 2006-05-23 Herbert L. Heyneker Production of recombinant polypeptides by bovine species and transgenic methods
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
DE69433925T2 (de) * 1993-06-10 2005-07-28 Bayer Corp. Vektoren und Zelllinien von Säugetieren mit erhöhter Produktivität
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6180108B1 (en) 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus

Similar Documents

Publication Publication Date Title
BE2018C020I2 (https=)
BE2016C007I2 (https=)
BE2015C018I2 (https=)
BE2014C017I2 (https=)
BE2013C051I2 (https=)
BE2013C020I2 (https=)
BE2013C015I2 (https=)
BE2013C001I2 (https=)
BE2012C036I2 (https=)
JP2002509754A5 (https=)
BE2010C011I2 (https=)
BRPI0017527B8 (https=)
BE2008C047I2 (https=)
JP2002516484A5 (https=)
BE2011C004I2 (https=)
BRPI0001672A2 (https=)
BRPI0001542A2 (https=)
BRPI0012675B8 (https=)
JP2001055402A5 (https=)
JP2002519235A5 (https=)
BRPI0017522A2 (https=)
HU0004776D0 (https=)
JP2002518167A5 (https=)
IN188930B (https=)
BRMU7902607U2 (https=)